Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Srdan Verstovsek, MD PhD, Miklos Egyed, MD PhD, Ewa Lech-Marańda, MD PhD, Tomasz Sacha, MDPhD, Viviane Dubruille, MD, Stephen T. Oh, MD, Doroteya Todorieva-Todorova, MD, Francesco Passamonti, MD, Blanca Xicoy, MD, Björn Andréasson, MD PhD, Daniel El Fassi, MD, Claire Harrison, DM, FRCP, FRCPath, Donal P. McLornan, MRCP, PhD FRCPath, Mary Frances Frances McMullin, MDFRCPath,FRCP, Christof Scheid, MD, MArianne Tang Severinsen, MD PhD, Mark M Kowalski, MD PhD, Gregg Smith, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-135872

Published: 2020

Journal Articles

Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents

Malte Asshoff, Verena Petzer, Matthew R. Warr, David Haschka, Piotr Tymoszuk, Egon Demetz, Markus Seifert, Wilfried Posch, Manfred Nairz, Pat Maciejewski, Peter Fowles, Christopher J. Burns, Gregg Smith, Kay-Uwe Wagner, Guenter Weiss, J. Andrew Whitney, Igor Theurl

Blood (2017) 129 (13): 1823–1830.

https://doi.org/10.1182/blood-2016-09-740092

Published: 2017

Includes: Supplemental data

Journal Articles

Effect Of The JAK1/2 Inhibitor GS-0387 (momelotinib) On The Anemia Associated With a Preclinical Murine Model Of Human Primary Myelofibrosis

Jean-Luc Villeval, PhD, Claudine Moratal, M2, Franck Debeurme, Catherine Lacout, Eric Solary, MD, PhD, William Vainchenker, MD, PhD, Christopher J Burns, PhD, Gregg Smith, PhD

Blood (2013) 122 (21): 2851.

https://doi.org/10.1182/blood.V122.21.2851.2851

Published: 2013

Journal Articles

An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,

Animesh Pardanani, MBBS, PhD, Jason Gotlib, M.D., M.S., Vikas Gupta, MD, FRCP, FRCPath, Andrew W Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Mark R. Litzow, MD, William J Hogan, MBBCh, Kebede Begna, MD, Gregg Smith, PhD, MBA, Linda M Bavisotto, MD, Mark Kowalski, MD, PhD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 3849.

https://doi.org/10.1182/blood.V118.21.3849.3849

Published: 2011

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents

Effect Of The JAK1/2 Inhibitor GS-0387 (momelotinib) On The Anemia Associated With a Preclinical Murine Model Of Human Primary Myelofibrosis

An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,

Email alerts

ASH Publications

American Society of Hematology

Update search

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents

Effect Of The JAK1/2 Inhibitor GS-0387 (momelotinib) On The Anemia Associated With a Preclinical Murine Model Of Human Primary Myelofibrosis

An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only